Patent Assignment
Reel/Frame 056958/0493
Security Agreement
Recorded: 2021-07-22
Pages: 14
Assignee
U.S. BANK NATIONAL ASSOCIATION
100 WALL STREET, SUITE 600, NEW YORK, NEW YORK, 10005
Covered Properties
(123)
Processes and Apparatus for Extraction of Active Substances and Enriched Extracts from Natural Products
Processes and Apparatus for Extraction of Active Substances and Enriched Extracts from Natural Products
Processes and Apparatus for Extraction of Active Substances and Enriched Extracts from Natural Products
Extraction of Pharmaceutically Active Components from Plant Materials
Compositions Comprising Cannabinoids for Treatment of Nausea, Vomiting, Emesis, Motion Sickness or Like Conditions
Compositions Comprising Cannabinoids for Treatment of Nausea, Vomiting, Emesis, Motion Sickness or Like Conditions
Application:
16/532,985 →
Publication:
US US20200206151A1
Dose Dispensing System and Apparatus
Methods of Purifying Cannabinoids from Plant Material
Methods of Preparing Cannabinoids From Plant Material
Pharmaceutical compositions comprising cannabichromene type compounds
Use for Cannabinoid
Use for Cannabinoid
Pharmaceutical Compositions Comprising Cannabigerol
Inhibition of Tumour Cell Migration
Application:
16/143,094 →
Publication:
US US20190255011A1
Extraction of Pharmaceutically Active Components from Plant Materials
Application:
16/904,643 →
Publication:
US US20210128657A1
Novel Reference Plant, a Method for Its Production, Extracts Obtained Therefrom and Their Use
Cannabinoids in Combination with Non-Cannabinoid Chemotherapeutic Agents
Application:
17/102,109 →
Publication:
US US20210069333A1
Use of One or a Combination of Phyto-Cannabinoids in the Treatment of Epilepsy
Phytocannabinoids in the Treatment of Cancer
Phytocannabinoids in the Treatment of Cancer
Phytocannabinoids in the Treatment of Cancer
Application:
15/620,435 →
Publication:
US US20180042975A1
Cannabinoids for Use in the Treatment of Neuropathic Pain
Cannabinoids for Use in the Treatment of Neuropathic Pain
Application:
16/142,394 →
Publication:
US US20190224140A1
Cannabinoids for Use in the Treatment of Neurodegenerative Diseases or Disorders
Phytocannabinoids for Use in the Treatment of Intestinal Inflammatory Diseases
Use of Tetrahydrocannabinol and/or Cannabidiol for Increasing Radiosensitivity in the Treatment of a Brain Tumour
Use of Cannabinoids in the Treatment of Mental Disorders
Use of Cannabinoids in the Treatment of Mental Disorders
Application:
16/845,204 →
Publication:
US US20210059959A1
Use of Cannabinoids in the Treatment of Inflammatory Skin Diseases
Device, Method and Resistive Element for Vaporising a Medicament
Use of Cannabinoids in Combination with an Anti-Psychotic Medicament
Anti-Tumoural Effects of Cannabinoid Combinations
Use of the Phytocannabinoid Cannabidivarin (Cbdv) in the Treatment of Epilepsy
Use of the Phytocannabinoid Cannabidivarin (Cbdv) in the Treatment of Epilepsy
Use of the Phytocannabinoid Cannabidivarin (Cbdv) in the Treatment of Epilepsy
Use of the Phytocannabinoid Cannabidiol (Cbd) in Combination with a Standard Anti-Epileptic Drug (Saed) in the Treatment of Epilepsy
Application:
13/977,766 →
Publication:
US US20140155456A9
A Pharmaceutical Composition Comprising the Phytocannabinoids Cannabidivarin (Cbdv) and Cannabidiol (Cbd)
Pharmaceutical Composition Comprising the Phytocannabinoids Cannabidivarin (CBDV) and Cannabidiol (CBD)
Use of One or a Combination of Phyto-Cannabinoids in the Treatment of Epilepsy
Secure Container for Holding Liquid Medicaments
Patent:
559,396 →
Application:
29/252,892 →
Hand-Held Electronic Device
Patent:
562,316 →
Application:
29/252,926 →
Pharmaceutical Formulations
Pharmaceutical Formulation
Pharmaceutical Formulation
Pharmaceutical Formulation
Pharmaceutical Compositions for the Treatment of Pain
Method for the Treatment of Constipation
Pharmaceutical Compositions for the Treatment of Disease and/or Symptoms in Arthritis
Application:
16/562,515 →
Publication:
US US20200206184A1
Pharmaceutical Formulation
Cannabinoid-Containing Plant Extracts as Neuroprotective Agents
Cannabinoid-Containing Plant Extracts as Neuroprotective Agents
Pharmaceutical Formulation
Pharmaceutical Formulation
Pharmaceutical Formulation
Synergistic Therapies of Cannabidiol with Hypothermia for Neuroprotection
Tetrahydrocannabivarin for Use in the Treatment of Nausea and Vomiting
The Use of Phytocannabinoids in the Treatment of Ovarian Carcinoma
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Active Pharmaceutical Ingredient (Api) Comprising Cannabinoids for Use in the Treatment of Cancer
7-Hydroxy Cannabidiol (7-Oh-Cbd) for Use in the Treatment of Non-Alcoholic Fatty Liver Disease (Nafld)
7-Oh-Cannabidiol (7-Oh-Cbd) and/or 7-Oh-Cannabidivarin (7-Oh-Cbdv) for Use in the Treatment of Epilepsy
Use of Cannabidiol in the Treatment of Epilepsy
Use of Cannabidiol in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabidiol in the Treatment of Epilepsy
Use of Cannabidiol in the Treatment of Nocturnal Snoring
Application:
15/519,244 →
Publication:
US US20170239193A1
Use of Cannabinoids in the Treatment of Degenerative Skeletal Muscle Diseases
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Application:
16/737,707 →
Publication:
US US20200138738A1
Use of Cannabidiolic Acid in the Treatment of Autism Spectrum Disorder and Associated Disorders
Use of Cannabidiolic Acid in the Treatment of Autism Spectrum Disorder and Associated Disorders
Use of Cannabidivarin in the Treatment of Autism Spectrum Disorder, Associated Disorders and Schizophrenia
Parenteral Formulations
Oral Cannabinoid Formulations
Cannabinoid Formulations
Application:
15/640,033 →
Publication:
US US20180071210A1
Use of Cannabinoids in the Treatment of Multiple Myeloma
Use of Cannabinoids in the Treatment of Angelman Syndrome
Oral Cannabinoid Formulations
Combination of Cannabinoids in the Treatment of Leukaemia
Combination of Cannabinoids in the Treatment of Leukemia
Use of Cannabinoids in the Treatment of Epilepsy
Application:
16/791,940 →
Publication:
US US20200179303A1
Use of Cannabinoids in the Treatment of Epilepsy
Application:
16/989,605 →
Publication:
US US20200368179A1
Use of Cannabidiol in the Treatment of Tuberous Sclerosis Complex
Application:
16/624,106 →
Publication:
US US20200206153A1
Use of Cannabinoids in the Treatment of a Neurodegenerative Disease or Disorder
Use of Cannabidiol in Combination with 5-HT2B Receptor Agonists or Amphetamines in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Seizures as Associated with Lennox-Gastaut Syndrome
Application:
16/764,701 →
Publication:
US US20210169824A1
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Pharmaceutical Composition Comprising a Cannabinoid
Modified Release Composition Comprising a Cannabinoid
Application:
16/959,354 →
Publication:
US US20210059949A1
Oral Pharmaceutical Formulation Comprising Cannabinoids and Poloxamer
Application:
16/959,357 →
Publication:
US US20210059976A1
Use of Cannabinoids in the Treatment of Epilepsy
Application:
16/960,665 →
Publication:
US US20200352878A1
Cannabidiol Preparations and Its Uses
High Cannabidiol Containing Cannabis Chemotypes
Application:
17/050,956 →
Publication:
US US20210052512A1
Pharmaceutical Formulation
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Cannabidiol-Type Cannabinoid Compound
Application:
17/296,066 →
Publication:
US US20220016048A1
Pharmaceutical Formulation
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabidiol in the Treatment of Epilepsy
Application:
16/935,005 →
Publication:
US US20210330636A1
Use of Cannabinoids in the Treatment of Epilepsy
Application:
17/025,130 →
Publication:
US US20220087951A1
Ph Dependent Release Coated Microparticle Cannabinoid Formulations
Patent:
11,160,757 →
Application:
17/068,326 →
Methods of Treating Tuberous Sclerosis Complex with Cannabidiol and Everolimus
Pharmaceutical formulations
Use of Cannabinoids in the Treatment of Epilepsy
Use of Cannabidiol in the Treatment of Epilepsy
Pharmaceutical Compositions
Related Assignments
(11)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Dec 15, 2009
From: WHITTLE, BRIAN; GUY, GEOFFREY; DOWNS, DAVID; PATE, DAVID W.
To: GW PHARMA LIMITED
Reel/Frame 023652/0858 →
Assignment of Assignor's Interest
Jun 8, 2015
From: WHITTLE, BRIAN; GUY, GEOFFREY; DOWNS, DAVID; PATE, DAVID W.
To: GW PHARMA LIMITED
Reel/Frame 035802/0698 →
Assignment of Assignor's Interest
Sep 24, 2015
From: GUY, GEOFFREY WILLIAM; PERTWEE, ROGER
To: GW PHARMA LIMITED
Reel/Frame 036643/0005 →
Assignment of Assignor's Interest
Feb 18, 2016
From: WHALLEY, BENJAMIN; STEPHENS, GARY; WILLIAMS, CLAIRE; GUY, GEOFFREY
To: GW PHARMA LIMITED; OTSUKA PHARMACEUTICAL CO., LIMITED
Reel/Frame 037767/0204 →
Assignment of Assignor's Interest
Nov 17, 2017
From: OTSUKA PHARMACEUTICAL CO., LIMITED
To: GW PHARMA LIMITED
Reel/Frame 044162/0001 →
Remove Pat No 9,066,920 at Reel/Frame 044162/0001 -- the Deed of Assignment Recorded at Reel/Frame 044162/0001 Did Not Convey Pat No 9,066,920
Nov 7, 2018
From: OTSUKA PHARMACEUTICAL CO., LIMITED
To: GW PHARMA LIMITED
Reel/Frame 048407/0325 →
Assignment of Assignor's Interest
Jan 23, 2020
From: WHITTLE, BRIAN; JAVID, FARIDEH AFSHIN
To: GW PHARMA LIMITED
Reel/Frame 051593/0534 →
Assignment of Assignor's Interest
Aug 11, 2023
From: DIEZ, GUILLERMO VELASCO; PASTOR, MANUEL GUZMAN; LORENTE, MAR; TORRES, SOFIA
To: GW PHARMA LIMITED; OTSUKA PHARMACEUTICAL CO., LTD.
Reel/Frame 064567/0063 →
Assignment of Assignor's Interest
Aug 11, 2023
From: OTSUKA PHARMACEUTICAL CO., LIMITED
To: GW PHARMA LIMITED
Reel/Frame 064566/0980 →
Change of Name
May 13, 2025
From: GW PHARMA LIMITED
To: JAZZ PHARMACEUTICALS OPERATIONS UK LIMITED
Reel/Frame 071097/0088 →
Change of Name
May 13, 2025
From: GW PHARMA LIMITED
To: JAZZ PHARMACEUTICALS OPERATIONS UK LIMITED
Reel/Frame 071104/0173 →